STOCK TITAN

FibroBiologics (FBLG) SEC Filings, Jul-Sep 2026

FBLG NASDAQ

FibroBiologics, Inc. filings document the regulatory record of a clinical-stage biotechnology issuer developing fibroblast-based therapies. Recent disclosures cover registered equity financing through an at-the-market common stock program, shelf registration mechanics, common stock and warrant-related capital structure matters, and corporate uses of proceeds for working capital and general corporate purposes.

The company’s SEC filings also record governance and public-company administration, including annual meeting proxy proposals, director election and auditor ratification matters, stock-plan option grants to executive officers, Nasdaq continued-listing compliance, amendments to stockholder-meeting quorum provisions, and material agreements affecting its operating footprint.

Rhea-AI Summary

FibroBiologics, Inc. (FBLG) entered into a securities purchase agreement on September 15, 2026 with its Chief Scientific Officer, Hamid Khoja, Ph.D., for a private placement of 298,508 shares of common stock and accompanying warrants to purchase up to 298,508 additional shares.

The securities are priced at $1.675 per share and accompanying warrant, reflecting a $1.55 consolidated closing bid price on September 14, 2026 plus $0.125 per warrant, for expected gross proceeds of approximately $0.5 million before expenses. The warrants are immediately exercisable at $1.55 per share, have a five-year term, include cashless exercise features and standard anti-dilution adjustments, and may result in up to an additional 298,508 shares being issued. The transaction relies on Section 4(a)(2) and Rule 506(b) exemptions and is intended for general corporate purposes and working capital.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.10%
Tags
current report
-
Rhea-AI Summary

FibroBiologics, Inc. (symbol FBLG) filed an initial statement of beneficial ownership on Form 3 for Leigh Steinberg. Steinberg is identified as a director of the company and is not listed as an officer or a ten percent owner. The filing also references an Exhibit 24 Power of Attorney.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.58%
Tags
insider
-
Rhea-AI Summary

FibroBiologics, Inc. (FBLG), a clinical-stage biotechnology company focused on fibroblast-based therapeutics, reported that its Board appointed Leigh Steinberg as a Class II director effective August 20, 2026, with a term running until the 2028 annual meeting of stockholders. He will receive compensation consistent with other non-employee directors under the company’s Non-Employee Director Compensation Policy and has entered into FibroBiologics’ standard indemnification agreement. The company states that Mr. Steinberg has no related-party transactions requiring disclosure and was not appointed pursuant to any arrangements with other persons. A press release furnished as an exhibit highlights his five decades of sports agency experience, his advocacy for human longevity and brain health, and FibroBiologics’ portfolio of more than 270 patents issued and pending.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.25%
Tags
current report
Rhea-AI Summary

FibroBiologics, Inc. has a significant shareholder group reporting passive ownership. Armistice Capital, LLC and Steven Boyd, as joint reporting persons, report beneficial ownership of 738,977 shares of FibroBiologics common stock, representing 9.99% of the class.

The shares are held by Armistice Capital Master Fund Ltd., for which Armistice Capital is investment manager with shared voting and dispositive power over all 738,977 shares. The Master Fund has the economic right to receive dividends and sale proceeds, while Armistice Capital and Mr. Boyd may be deemed to share voting and investment power under an Investment Management Agreement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.83%
Tags
ownership
-
Rhea-AI Summary

FibroBiologics, Inc. is a clinical-stage cell-therapy company developing fibroblast-based treatments for chronic diseases. For the three and six months ended June 30, 2026, it reported net losses of $4,117 thousand and $9,117 thousand, driven by research and development expenses of $1,658 thousand and $4,611 thousand and general, administrative and other expenses of $2,375 thousand and $4,490 thousand, respectively.

Cash and cash equivalents were $3,515 thousand and total assets $7,929 thousand as of June 30, 2026, with net cash used in operating activities of $7,655 thousand in the first half. The company raised capital through a March SEPA draw, an April registered offering (including common stock and pre-funded warrants), an at-the-market program, and a June private placement of $3,000 thousand of pre-funded warrants plus accompanying warrants, contributing to additional paid-in capital of $67,916 thousand. Management states that its cash balance, continued losses and lack of revenue raise substantial doubt about its ability to continue as a going concern.

The pipeline advanced with a Phase 1/2 diabetic foot ulcer trial of CYWC628 in Australia, though enrollment is slower than planned; interim six-week data are expected after a defined number of patients per arm complete treatment. The company also discloses a Nasdaq Staff Determination to delist its securities for bid-price noncompliance and has requested a hearing, which temporarily stays delisting while it seeks to regain compliance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.93%
Tags
quarterly report
-
Rhea-AI Summary

FibroBiologics, Inc. is calling a virtual special meeting on September 17, 2026 to seek stockholder approval, under Nasdaq Listing Rule 5635(d), for the potential issuance of up to 8,163,266 shares of common stock upon exercise of outstanding Warrants under a June 25, 2026 securities purchase agreement and up to 285,714 shares upon exercise of Placement Agent Warrants.

These Warrants carry exercise prices of $0.735 and $0.9188 per share; if fully exercised they would yield approximately $6.0 million and $263 thousand in gross proceeds, respectively, but would dilute existing holders through new common shares.

As of July 20, 2026 there were 6,658,193 common shares outstanding and 125 super-voting Series C Preferred shares, each with 13,000 votes. The Board holds an irrevocable proxy over these preferred shares and plans to cast 1,625,000 votes, about 20% of eligible votes, in favor of the proposal. If approval is not obtained, the company states it cannot issue shares above Nasdaq’s 20% threshold under these Warrants and may owe liquidated damages, potentially straining liquidity and requiring emergency financing, while repeated stockholder meetings every 90 days would add legal cost and management distraction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.67%
Tags
proxy
Rhea-AI Summary

FibroBiologics, Inc. reports that Nasdaq’s Listing Qualifications staff issued a Staff Determination on July 22, 2026 to delist its securities from The Nasdaq Capital Market. The notice cites noncompliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share.

The company’s bid price closed below $1.00 for 30 consecutive business days from June 8 through July 21, 2026. Because FibroBiologics effected a reverse stock split within the prior year, it is not eligible for the usual 180-day cure period under Nasdaq Listing Rule 5810(c)(3)(A)(iv). Unless it requests an appeal by July 29, 2026, trading is expected to be suspended at the opening of business on July 31, 2026. FibroBiologics intends to timely request a hearing before a Nasdaq Hearings Panel, which will stay delisting actions during the hearing process, but there is no assurance the appeal or any plan to regain compliance will succeed.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.92%
Tags
current report
-
Rhea-AI Summary

FibroBiologics, Inc. is calling a virtual special stockholder meeting on September 17, 2026 to vote on a single proposal required by Nasdaq Listing Rule 5635(d). Stockholders are asked to approve the potential issuance of up to 8,163,266 shares of common stock upon exercise of outstanding investor warrants issued under a June 25, 2026 Securities Purchase Agreement and up to 285,714 shares upon exercise of outstanding Placement Agent Warrants issued under an engagement with H.C. Wainwright & Co.

As of the July 20, 2026 record date, there were 6,080,560 common shares and 125 Series C Preferred shares outstanding, with the preferred carrying 13,000 votes per share and subject to an irrevocable proxy in favor of the Board. Full warrant exercise would significantly dilute existing holders but could generate approximately $6.0 million from investor warrants and $263 thousand from Placement Agent Warrants. If the proposal is not approved, FibroBiologics may be unable to issue all warrant shares and could owe liquidated damages under the warrant terms, potentially straining liquidity and requiring repeated stockholder meetings every 90 days until approval is obtained.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.46%
Tags
proxy
-
EFFECT
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
other
Rhea-AI Summary

FibroBiologics, Inc. is registering for resale up to 12,530,613 shares of common stock issuable from June 2026 private‑placement warrants, including Pre-Funded, Short-term, Long-term and placement agent warrants. Existing investors, not the company, will sell these shares from time to time.

FibroBiologics will not receive proceeds from stockholder resales but may obtain up to approximately $6.3 million in gross proceeds if the June Warrants are exercised for cash. Common stock outstanding was 6,080,560 shares as of July 8, 2026, rising to 18,611,173 shares if all such warrants are exercised.

The company recently executed a 1-for-20 reverse stock split, completed an April 2026 equity offering with approximately $2.5 million in net proceeds, and established a $7.5 million at-the-market program, while regaining Nasdaq bid-price and equity listing compliance subject to one-year monitoring periods.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
prospectus

FAQ

How many FibroBiologics (FBLG) SEC filings are available on StockTitan?

StockTitan tracks 75 SEC filings for FibroBiologics (FBLG), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for FibroBiologics (FBLG)?

The most recent SEC filing for FibroBiologics (FBLG) was filed on October 20, 2026.